

# Jay D Horton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6117586/publications.pdf>

Version: 2024-02-01

50  
papers

26,299  
citations

101384

36  
h-index

205818

48  
g-index

52  
all docs

52  
docs citations

52  
times ranked

27971  
citing authors

#	ARTICLE	IF	CITATIONS
1	SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. <i>Journal of Clinical Investigation</i> , 2002, 109, 1125-1131.	3.9	3,528
2	Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. <i>Hepatology</i> , 2004, 40, 1387-1395.	3.6	3,250
3	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
4	SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. <i>Journal of Clinical Investigation</i> , 2002, 109, 1125-1131.	3.9	2,177
5	Human Fatty Liver Disease: Old Questions and New Insights. <i>Science</i> , 2011, 332, 1519-1523.	6.0	1,780
6	Molecular mediators of hepatic steatosis and liver injury. <i>Journal of Clinical Investigation</i> , 2004, 114, 147-152.	3.9	1,571
7	Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12027-12032.	3.3	1,233
8	Molecular mediators of hepatic steatosis and liver injury. <i>Journal of Clinical Investigation</i> , 2004, 114, 147-152.	3.9	944
9	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776
10	Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. <i>Journal of Biological Chemistry</i> , 2007, 282, 18602-18612.	1.6	660
11	Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 5374-5379.	3.3	637
12	Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus. <i>Journal of Biological Chemistry</i> , 1999, 274, 30028-30032.	1.6	616
13	Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. <i>Journal of Clinical Investigation</i> , 2006, 116, 2995-3005.	3.9	587
14	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. <i>New England Journal of Medicine</i> , 2017, 376, 41-51.	13.9	571
15	Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c. <i>Journal of Biological Chemistry</i> , 2002, 277, 9520-9528.	1.6	563
16	Acetate Dependence of Tumors. <i>Cell</i> , 2014, 159, 1591-1602.	13.5	524
17	PCSK9: a convertase that coordinates LDL catabolism. <i>Journal of Lipid Research</i> , 2009, 50, S172-S177.	2.0	517
18	Molecular biology of PCSK9: its role in LDL metabolism. <i>Trends in Biochemical Sciences</i> , 2007, 32, 71-77.	3.7	512

#	ARTICLE	IF	CITATIONS
19	Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver. <i>Journal of Biological Chemistry</i> , 2004, 279, 50630-50638.	1.6	442
20	Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire Program of Unsaturated Fatty Acid Biosynthesis in Transgenic Mouse Liver. <i>Journal of Biological Chemistry</i> , 1998, 273, 35299-35306.	1.6	320
21	SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. <i>Genes and Development</i> , 2001, 15, 1206-1216.	2.7	279
22	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. <i>Cell Metabolism</i> , 2017, 26, 394-406.e6.	7.2	265
23	The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals. <i>Cell Metabolism</i> , 2012, 15, 240-246.	7.2	263
24	Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. <i>Journal of Clinical Investigation</i> , 2004, 113, 1168-1175.	3.9	218
25	MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. <i>Nature Medicine</i> , 2015, 21, 1280-1289.	15.2	203
26	Overexpression of Sterol Regulatory Element-binding Protein-1a in Mouse Adipose Tissue Produces Adipocyte Hypertrophy, Increased Fatty Acid Secretion, and Fatty Liver. <i>Journal of Biological Chemistry</i> , 2003, 278, 36652-36660.	1.6	195
27	Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. <i>Journal of Lipid Research</i> , 2009, 50, 412-423.	2.0	181
28	Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. <i>Journal of Clinical Investigation</i> , 1999, 103, 1067-1076.	3.9	174
29	CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. <i>Nature Communications</i> , 2016, 7, 10961.	5.8	165
30	Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. <i>Journal of Lipid Research</i> , 2018, 59, 475-487.	2.0	148
31	Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1189-1194.	3.3	143
32	An adipo-biliary-uridine axis that regulates energy homeostasis. <i>Science</i> , 2017, 355, .	6.0	90
33	Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. <i>ELife</i> , 2017, 6, .	2.8	82
34	An acetate switch regulates stress erythropoiesis. <i>Nature Medicine</i> , 2014, 20, 1018-1026.	15.2	62
35	Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance. <i>Journal of Lipid Research</i> , 2014, 55, 2597-2605.	2.0	61
36	Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. <i>Journal of Lipid Research</i> , 2017, 58, 1661-1669.	2.0	41

#	ARTICLE	IF	CITATIONS
37	AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. <i>Molecular Metabolism</i> , 2016, 5, 491-505.	3.0	36
38	Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. <i>Molecular Metabolism</i> , 2018, 14, 121-129.	3.0	35
39	Adipocyte Xbp1s overexpression drives uridine production and reduces obesity. <i>Molecular Metabolism</i> , 2018, 11, 1-17.	3.0	34
40	Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2 <sup>-/-</sup> ) or obese (ob/ob) mice. <i>Journal of Lipid Research</i> , 2016, 57, 616-630.	2.0	29
41	The impact of endotrophin on the progression of chronic liver disease. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1766-1776.	3.2	25
42	Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
43	Unfolding Lipid Metabolism. <i>Science</i> , 2008, 320, 1433-1434.	6.0	11
44	Delisting <i>STAP1</i> . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 847-849.	1.1	10
45	CB1Rs in VMH neurons regulate glucose homeostasis but not body weight. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E146-E155.	1.8	9
46	Intravascular triglyceride lipolysis becomes crystal clear. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1480-1482.	3.3	7
47	Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166167.	1.8	5
48	Response to Kunos et al. and Lotersztajn and Mallat. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	1
49	Statins Induce Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9. <i>FASEB Journal</i> , 2008, 22, 1040.4.	0.2	0
50	Abstract 61: LXR Agonist Treatment of Nonhuman Primates Increases LDL Cholesterol due to Decreased Hepatic LDL Receptor Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0